Elite Pharmaceuticals, Inc. Watch

from 10-K 28 pages Material contract

from 10-K 17 pages Elite Pharmaceuticals, Inc. Restated 2014 Equity Incentive Plan Section 1 Introduction

from 8-K 11 pages Employment Agreement

from 8-K 2 pages April 27, 2023 Personal and Confidential

from 8-K 11 pages Employment Agreement

from 10-Q 31 pages Material contract

from 10-Q 23 pages Material contract

from 10-K 34 pages Explanatory Note: [***] Indicates the Portion of This Exhibit That Has Been Omitted Because It Is Both (I) Not Material and (II) Would Be Competitively Harmful if Publicly Disclosed License, Supply and Distribution Agreement for Vigabatrin Elite Pharmaceuticals, Inc., Elite Laboratories, Inc., - And - Lannett Company, Inc. Dated as of July 20, 2021 Explanatory Note: [***] Indicates the Portion of This Exhibit That Has Been Omitted Because It Is Both (I) Not Material and (II) Would Be Competitively Harmful if Publicly Disclosed

from 10-K 2 pages Explanatory Note: [***] Indicates the Portion of This Exhibit That Has Been Omitted Because It Is Both (I) Not Material and (II) Would Be Competitively Harmful if Publicly Disclosed

from 10-K 52 pages Explanatory Note: [***] Indicates the Portion of This Exhibit That Has Been Omitted Because It Is Both (I) Not Material and (II) Would Be Competitively Harmful if Publicly Disclosed Supply & Distribution Agreement

from 10-K 2 pages - Signature Page Follows - 1

from 10-K 2 pages - Signature Page Follows - 1

from 8-K 2 pages May 5, 2022 Personal and Confidential

from 10-Q 18 pages Explanatory Note: [***] Indicates the Portion of This Exhibit That Has Been Omitted Because It Is Both (I) Not Material and (II) Would Be Competitively Harmful if Publicly Disclosed Master Development and License Agreement for Products Between Elite Pharmaceuticals, Inc. and Mikah Pharma LLC Article 1 Definitions

from 10-K 4 pages Explanatory Note: [***] Indicates the Portion of This Exhibit That Has Been Omitted Because It Is Both (I) Not Material and (II) Would Be Competitively Harmful in Publicly Disclosed. First Amendment to the License, Supply and Distribution Agreement Between Elite Pharmaceuticals, Inc./Elite Laboratories, Inc. and Lannett Company, Inc

from 10-K 2 pages June 21, 2019 Personal and Confidential

from 10-K 4 pages July 20, 2013 Personal and Confidential

from 8-K 2 pages April 26, 2021 Personal and Confidential

from 10-Q 1 page Elite Pharmaceuticals, Inc. Has Entered Into an Equity Line Purchase Agreement With Lincoln Park Capital Fund LLC (The “2020 Lpc Agreement”) to Replace the Prior Equity Line Purchase Agreement With Lincoln Park That Expired on July 1, 2020 (The “2017 Lpc Agreement”). Pursuant to the Terms of My Series J Preferred Stock and Series J Warrants (Collectively, the “Series J Securities”), Transactions Pursuant to the 2017 Lpc Agreement Were Excluded From the Anti-Dilution Provisions of the Series J Securities. I Hereby Waive My Rights Under the Anti-Dilution Provisions of the Series J Securities With Regard to Transactions Under the 2020 Lpc Agreement. Very Truly Yours, By: /S/ Nasrat Hakim Nasrat Hakim

from 8-K/A 19 pages Asset Purchase Agreement